Supernus Provides Regulatory Update for SPN-830
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Jefferies on Supernus (SUPN): 'We expect a -5-10% stock reaction after the FDA's rejection of SPN-830'
April 8, 2024 10:10 AM EDTJefferies analyst Irene Buhalo reiterated a Buy rating and $40.00 price target on Supernus Pharmaceuticals (NASDAQ: SUPN)
The analyst comments "We expect a -5-10% stock reaction after the FDA's rejection of SPN-830 (apomorphine pump) in Parkinson's. Street expectations were fairly low,... More
Stifel on Supernus Pharmaceuticals (SUPN): 'SPN-830 Approval Delayed Again, but Near-Term Impact Relatively Minor'
April 8, 2024 10:09 AM EDTStifel analyst Annabel Samimy reiterated a Hold rating and $38.00 price target on Supernus Pharmaceuticals (NASDAQ: SUPN).
The analyst comments "SUPN announced that the resubmission review of SPN-830 (apomorphine infusion pump for PD) has been met with another CRL. Specifically, FDA is requesting additional... More
